



(12) Translation of
European patent specification

(11) NO/EP 3195875 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 38/24 (2006.01)
A61P 5/06 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.11.12
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.07.25
(86)	European Application Nr.	17154031.3
(86)	European Filing Date	2012.08.08
(87)	The European Application's Publication Date	2017.07.26
(30)	Priority	2011.08.08, EP, 11176803
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Ferring BV, Polaris Avenue 144, 2132 JX Hoofddorp, Nederland
(72)	Inventor	ARCE, Joan-Carles, Soevej 100, DK-2791 Dragoer, Danmark
(74)	Agent or Attorney	OSLO PATENTKONTOR AS, Postboks 7007 M, 0306 OSLO, Norge

(54)	Title	COMPOSITION FOR CONTROLLED OVARIAN STIMULATION
(56)	References Cited:	WO-A1-2009/127826, WO-A1-2012/042381, US-A1- 2008 108 571, ANCKAERT ELLEN ET AL: "The value of anti-Mullerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments.", June 2012 (2012-06), HUMAN REPRODUCTION (OXFORD, ENGLAND) JUN 2012 LNKD- PUBMED:22473395, VOL. 27, NR. 6, PAGE(S) 1829 - 1839, XP002686253, ISSN: 1460-2350 * the whole document *, FREIESLEBEN N L C ET AL: "Prospective investigation of serum anti-Mullerian hormone concentration in ovulatory intrauterine insemination patients: a preliminary study", REPRODUCTIVE BIOMEDICINE ONLINE, REPRODUCTIVE HEALTHCARE LTD, GB, vol. 20, no. 5, 1 May 2010 (2010-05-01), pages 582-587, XP027030875, ISSN: 1472-6483 [retrieved on 2010-02-12], LA COUR FREIESLEBEN N ET AL: "Individual versus standard dose of rFSH in a mild stimulation protocol for intrauterine insemination: a randomized study.", HUMAN REPRODUCTION (OXFORD, ENGLAND) OCT 2009 LNKD- PUBMED:19602518, vol. 24, no. 10, October 2009 (2009-10), pages 2523-2530, XP002666778, ISSN: 1460-2350, U.S. National Institute of Health: "A Dose-response Trial Using rFSH FE999049 in Women Undergoing IVF/ICSI Treatment", , 30 August 2011 (2011-08-30), XP002666779, Retrieved from the Internet: URL:http://clinicaltrials.gov/ct2/show/NCT01426386?term=fe+999049&rank=1 [retrieved on 2012-01-10], FLACK M R ET AL: "Increased biological activity due to basic isoforms in recombinant human follicle-stimulating hormone produced in a human cell line", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, THE ENDOCRINE SOCIETY, US, vol. 79, no. 3, 1 September 1994 (1994-09-01), pages 756-760, XP002494715, ISSN: 0021-972X, DOI: 10.1210/JC.79.3.756

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Produkt omfattende FSH for anvendelse ved behandling av infertilitet hos et individ som har risiko for OHSS og som har et serum AMH-nivå på ≥ 15 pmol/l, hvor produktet skal administreres i en dose på, eller i en doseekvivalent til, 0,09 til 0,19
5 µg human celledinje-avledet rekombinant FSH per kilogram kroppsvekt av individet per dag, hvor FSH innbefatter α2, 3- og α2, 6-sialylering hvor 1% til 99% av den totale sialyleringen er α2, 6-sialylering.
2. Produkt for anvendelse ifølge krav 1, hvor behandlingen av infertilitet er ved kontrollert ovarie-stimulering.
- 10 3. Produkt for anvendelse ifølge et hvilket som helst av kravene 1 eller 2, hvor behandlingen av infertilitet innbefatter et trinn med bestemmelse av serum AMH-nivået hos individet.